Luo Dan, Bai Mengzhe, Zhang Wei, Wang Junnan
Department of Cardiology, Second Hospital of Jilin University, Changchun, Jilin, China.
Front Cardiovasc Med. 2024 May 27;11:1409723. doi: 10.3389/fcvm.2024.1409723. eCollection 2024.
ACE2 is the earliest receptor discovered to mediate the entry of SARS-CoV-2. In addition to the receptor, it also participates in complex pathological and physiological processes, including regulating the RAS system, apelin, KKS system, and immune system. In addition to affecting the respiratory system, viral infections also interact with cardiovascular diseases. SARS-CoV-2 can directly invade the cardiovascular system through ACE2; Similarly, cardiovascular diseases such as hypertension and coronary heart disease can affect ACE2 levels and exacerbate the disease, and ACE2 dysregulation may also be a potential mechanism for long-term acute sequelae of COVID-19. Since the SARS CoV-2 epidemic, many large population studies have tried to clarify the current focus of debate, that is, whether we should give COVID-19 patients ACEI and ARB drug treatment, but there is still no conclusive conclusion. We also discussed potential disease treatment options for ACE2 at present. Finally, we discussed the researchers' latest findings on ACE2 and their prospects for future research.
血管紧张素转换酶2(ACE2)是最早被发现介导严重急性呼吸综合征冠状病毒2(SARS-CoV-2)进入细胞的受体。除作为受体外,它还参与复杂的病理生理过程,包括调节肾素-血管紧张素系统(RAS系统)、apelin、激肽释放酶-激肽系统(KKS系统)及免疫系统。病毒感染除影响呼吸系统外,还与心血管疾病相互作用。SARS-CoV-2可通过ACE2直接侵入心血管系统;同样,高血压和冠心病等心血管疾病可影响ACE2水平并加重病情,而ACE2失调也可能是冠状病毒病(COVID-19)长期急性后遗症的潜在机制。自SARS-CoV-2疫情以来,许多大规模人群研究试图阐明当前争论的焦点,即是否应给予COVID-19患者血管紧张素转换酶抑制剂(ACEI)和血管紧张素Ⅱ受体阻滞剂(ARB)药物治疗,但仍未得出确凿结论。我们还讨论了目前针对ACE2的潜在疾病治疗方案。最后,我们讨论了研究人员关于ACE2的最新发现及其未来研究前景。